At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 511 enrolled
Drug / intervention
Regadenoson +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
In Brief
A Phase 4 clinical trial evaluating Regadenoson and Placebo for Kidney Diseases and Coronary Artery Disease. Completed, enrolled 511 participants across 41 sites.
Detailed Summary
This study is intended to assess the safety and tolerance of regadenoson in subjects with renal impairment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Diseases, Coronary Artery Disease
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2009
Enrollment StartApr 2009
Primary CompletionDec 2009
TodayJul 2026
First PostedMar 18, 2009
Enrollment StartApr 1, 2009
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.3 years ago
Interventions
Regadenosondrug
IV
Placebodrug
IV